DHX9 and tuberculosis: NDH-2 has been proposed as the molecular target of several potent antimycobacterial compounds including the phenothiazines13 and is thought to activate clofazimine (CFZ)14, a drug that has been used to treat leprosy for decades and is occasionally included in the treatment of multi-drug resistant (MDR) TB.